CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ReNeuron Group Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ReNeuron Group Plc
Pencoed Business Park
Phone: +44 2038198400p:+44 2038198400 BRIDGEND, CF35 5HY  United Kingdom Ticker: RENERENE
Placed into Administration on 3/20/2024
On 3/20/2024, ReNeuron Group Plc was placed into Administration along with its UK subsidiaries: ReNeuron Holdings Limited, ReNeuron Limited, and ReNeuron (UK) Limited, in the High Court of Justice Business and Property Courts of England and Wales. Mark Smith and Stephen Cork of Cork Gully LLP were appointed as the Administrators.
Business Summary
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. The Company’s CustomEX platform can be optimized for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Iain G.Ross 1/3/2023 7/2/2021
Chief Financial Officer, Director JohnHawkins 57 9/14/2022 6/1/2021
Chief Operations Officer SuzanneHancock 9/14/2022 7/1/2020
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ReNeuron Ireland Limited The Black Church, St. Mary's Place Dublin Ireland
ReNeuron (UK) Limited Pencoed Business Park, Pencoed Bridgend Wales United Kingdom
ReNeuron Holdings Limited Pencoed Business Park, Pencoed Bridgend Wales United Kingdom
ReNeuron Limited Pencoed Business Park, Pencoed Bridgend Wales United Kingdom

Business Names
Business Name
RENE
ReNeuron Holdings Limited
ReNeuron Holdings plc
ReNeuron Ireland Limited
RENEURON LIMITED

General Information
Number of Employees: 34 (As of 3/31/2023)
Outstanding Shares: 57,173,760 (As of 2/29/2024)
Shareholders: 31,374
Stock Exchange: LON
Fax Number: +44 1483534864


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024